Clinical trials: Osteomyelitis of Lower Extremities
Osteomyelitis - Foot
RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT)
The Study will be a prospective multicenter randomized trial, focused on the management of acute and chronic Osteomilytis in Diabetic Foot patients.
- Trial name
- DFORCT (NCT06388603)
- Testing
- Bioactive Glass, Standard of Care
- Where
- 7 sites in Italy
- Volunteers
- 140 people
- Sponsor
- ASST Ovest Milanese
Osteomyelitis, Bone Infection
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis
This clinical trial studies the clinical effectiveness of S53P4 bioactive glass (BAG) as a bacterial growth inhibiting bone graft substitute in a one-stage or two-stage surgical procedure for treatment of chronic long bone…
- Conditions
- Osteomyelitis, Bone Infection, Non-Union Fracture, Bone Infection of Lower Leg
- Trial name
- NCT04945434
- Testing
- S53P4 bioactive glass (BonAlive)
- Volunteers
- 78 people
- Sponsor
- Academisch Ziekenhuis Maastricht
Diabetes Mellitus, Diabetes Complications
New Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis
Diabetic foot wound infections are predominantly polymicrobial. However, 'conventional' microbiological culture does not identify all the bacteria potentially involved in these infections and requires time, which can have a…
- Conditions
- Diabetes Mellitus, Diabetes Complications, Diabetic Peripheral Neuropathy
- Trial name
- MINI-OS (NCT07391995)
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Diabetic Foot Ulcer, Osteomyelitis Chronic
Mirragen Diabetic Foot Ulcer Study
This study is being done to collect data from treatment of patients who have diabetes with non-healing foot wounds and are being treated with a resorbable and biocompatible borate-based bioactive glass fiber matrix.
- Trial name
- NCT06598241
- Testing
- Borate-base Bioactive Glass Fiber Matrix (BBGFM)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetic Foot
Less Infections for the Diabetic Foot
This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1.
- Trial name
- NCT03615807
- Testing
- Surgical debridement (if needed), Microbiological sampling, Revascularisation (if needed).
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- University Hospital, Geneva
Osteomyelitis, Diabetic Foot
Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers
Hypothesis:Surgical treatment of osteomyelitis in diabetic foot is more effective that medical treatment through antibiotherapy and leads wound healing in ulcers complicated with bone infection.Material and Methods: Randomized…
- Conditions
- Osteomyelitis, Diabetic Foot, Diabetic Foot Ulcers
- Trial name
- NCT01137903
- Testing
- Conservative surgery, Ciprofloxacin, Amoxicillin-Potassium Clavulanate Combination
- Where
- Spain
- Volunteers
- 88 people
- Sponsor
- Universidad Complutense de Madrid
Bone and Joint Infections
Clinical Evaluation of Daptomycin Bone Penetration
Bone and joint infections are commonly due to Gram-positive bacteria. Treatment of these infections is difficult because of the need of prolonged duration of antimicrobial agents in combination with surgical procedure.
- Trial name
- DAPTO-HUS (NCT01306825)
- Where
- 3 sites in France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Bacterial Infections, Diabetic Foot
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
- Conditions
- Bacterial Infections, Diabetic Foot, Osteomyelitis
- Trial name
- NCT00366249
- Testing
- Tigecycline, Ertapenem
- Where
- 211 sites in United States, Argentina and 37 more
- Volunteers
- 1,061 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabete Mellitus, Foot Ulcer
Efficacy and Safety of Stimulan® for the Treatment of Diabetic Foot Osteomyelitis. The BIG D-FOOT Study
This study is designed as a double-blind, placebo-controlled, parallel series randomized trial aimed at verifying the effiicacy and safety of a local calcium-sulphate bio-absorbable antibiotic delivery (tobramicina+vancomicina)…
- Conditions
- Diabete Mellitus, Foot Ulcer, Osteomyelitis - Foot, Surgical Procedure, Unspecified
- Trial name
- BIG D-FOOT (NCT06262854)
- Testing
- Calcium-sulphate granules with tobramicina+vancomicina
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi